Clinical research of transurethral turning holmium laser enucleation of the prostate in the treatment of benign prostatic hyperplasia

Objective To compare the efficacy and safety of turning holmium laser enucleation of the prostate (THoLEP) and transurethral holmium laser enucleation of the prostate (HoLEP) in the treatment of benign prostatic hyperplasia (BPH). Methods A retrospective analysis of 532 patients with BPH surgery from January 2016 to December 2017 was performed, including 289 cases of transurethral resection of holmium laser enucleation (THoLEP) and 43 cases of transurethral holmium laser enucleation (HoLEP). Cases with incomplete data were excluded. Finally, 100 patients were enrolled and divided into THoLEP group and HoLEP. The mean ages of patients in the THoLEP group and the HoLEP group were (74.6±8.2) years and (75.3±7.7) years, respectively. The prostate weights were (52.3±23.1) g and (52.6±22.7) g, respectively. International prostate symptom scores (IPSS) were (22.8±1.3) and (23.1±1.6), and the quality of life score (QOL) scores were (4.4±0.5) and (4.3±0.8), respectively. The rate of mximum flow rate (Qmax) was (5.9±2.7) ml/s and (6.3±2.8) ml/s, respectively. The residual urine volume was (149.3±8.7) ml and (145.3±9.7) ml, respectively. There was no significant difference between the two groups(P>0.05). Results Compared with HoLEP group, THoLEP group showed shorter operation time[(44±13)min vs.(61±15)min, P 0.05). The incidence of transient urinary incontinence in THoLEP group was less than that in HoLEP group [2 and 4 cases, P 0.05). Conclusions Compared with HoLEP, THoLEP has similar short-term results, and has more advantages in shortening the operation time, reducing intraoperative bleeding and transient urinary incontinence. It is a safer and effective method for the treatment of benign prostatic hyperplasia. Key words: Benign prostatic hyperplasia; Turning holmium laser; Enucleation of the prostate